ArticleInternational journal of colorectal disease2021
Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort.
Article in International journal of colorectal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Increasing colorectal cancer screening among Alaska Native peoples living in remote areas of Alaska: a multitarget stool DNA cluster randomized controlled trial.BMC primary care · 2026Trial
- Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.JCO precision oncology · 2026Observational
- Comparison of Benefit-to-Burden Ratios for Stool-Based Colorectal Cancer Screening Tests in the U.S.: A Decision Analytical Modeling Approach.AJPM focus · 2026Article
- Real-World Completion of Multitarget Stool DNA Testing Among Texas Medicare Beneficiaries: Associations With Payer Type, Digital Outreach, and Social Vulnerability.Journal of health economics and outcomes research · 2026Article
- Multitarget Stool DNA Testing for Colorectal Cancer Screening in Clinical Practice.The American journal of gastroenterology · 2025Article
- Adherence to multi-target stool DNA colorectal cancer screening and clinical follow-up in the Hartford HealthCare system.International journal of colorectal disease · 2025Article
- Adherence to Multitarget Stool DNA Testing in Individuals Aged 45-49 Years With Average Risk for Colorectal Cancer.Clinical and translational gastroenterology · 2025Article
- Novel colorectal cancer screening methods - opportunities and challenges.Nature reviews. Clinical oncology · 2025Review
- Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population.International journal of colorectal disease · 2025Article
- Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic.Journal of general internal medicine · 2025Article
- Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States.International journal of colorectal disease · 2025Article
- Navigating the evolving landscape of colorectal cancer screening with a practical framework: a comprehensive analysis of existing and emerging technologies for informed decision-making.Oncology reviews · 2025Review
- Utilization of molecular genetic approaches for colorectal cancer screening.World journal of gastroenterology · 2024Article
- Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- Barriers and facilitators of colorectal cancer screening using the 5As framework: A systematic review of US studies.Preventive medicine reports · 2023Review
- Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.Population health management · 2023Article
- Factors Associated with the Uptake of Genetic Testing for Cancer Risks: A Pathway Analysis Using the Health Information National Trends Survey Data.Life (Basel, Switzerland) · 2022Article
- Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a medicaid population.Preventive medicine reports · 2022Article
- Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population.Cancer prevention research (Philadelphia, Pa.) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer (CRC) is the second most deadly cancer in the USA. Early detection can improve CRC outcomes, but recent national screening rates (62%) remain below the 80% goal set by the National Colorectal Cancer Roundtable. Multiple options are endorsed for average-risk CRC screening, including the multi-target stool DNA (mt-sDNA) test. We evaluated cross-sectional mt-sDNA test completion in a population of commercially and Medicare-insured patients.
methodsParticipants included individuals ages 50 years and older with commercial insurance or Medicare, with a valid mt-sDNA test shipped by Exact Sciences Laboratories LLC between January 1, 2018, and December 31, 2018 (n = 1,420,460). In 2020, we analyzed cross-sectional adherence, as the percent of successfully completed tests within 365 days of shipment date.
resultsOverall cross-sectional adherence was 66.8%. Adherence was 72.1% in participants with Traditional Medicare, 69.1% in participants with Medicare Advantage, and 61.9% in participants with commercial insurance. Adherence increased with age: 60.8% for ages 50-64, 71.3% for ages 65-75, and 74.7% for ages 76 + years. Participants with mt-sDNA tests ordered by gastroenterologists had a higher adherence rate (78.3%) than those with orders by primary care clinicians (67.2%). Geographically, adherence rates were highest among highly rural patients (70.8%) and ordering providers in the Pacific region (71.4%).
conclusionsData from this large, national sample of insured patients demonstrate high cross-sectional adherence with the mt-sDNA test, supporting its role as an accepted, noninvasive option for average-risk CRC screening. Attributes of mt-sDNA screening, including home-based convenience and accompanying navigation support, likely contributed to high completion rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.